Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D Rapidly expanding use in the treatment of anemia FDA approved as first-line treatment of anemia in adults with lower-risk MDS OOX ㅁㅁ iber/mezi First and only therapy to demonstrate superiority over epoetin alpha in the head-to- head Phase 3 COMMANDS study Nearly doubled transfusion independence with concurrent hemoglobin increase vs epoetin alpha with a well-established safety profile Demonstrates more durable responses of transfusion independence vs epoetin alpha Expansion opportunities with ongoing studies in anemia associated with 1L TD MF, 1L NTD MDS, and alpha-thalassemia¹ Ill Bristol Myers Squibb™ 1. Asia-only study Not for Product Promotional Use 75

View entire presentation